Is Kiniksa Pharmaceuticals Ltd (KNSA) overvalued? · P/E 53, rev $423.2M
Kiniksa Pharmaceuticals Ltd (KNSA) is a drug manufacturers - specialty & generic company listed on US.
This page asks whether Kiniksa Pharmaceuticals Ltd (KNSA) looks expensive on cached numbers — not a short thesis.
Latest reported KNSA revenue for 2024-12-31 was $423.2M. Net income was -$43.2M. Revenue was up 56.6% from 2023-12-31 to 2024-12-31. KNSA currently screens at market cap $3.73B and trailing P/E 53.2.
KNSA currently screens at market cap $3.73B and trailing P/E 53.2. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next KNSA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the KNSA stock page for the full model, not this heading.
Not investment advice.